Stocks · News reference
Filed: 2026-06-12 AccNo: 0001493152-26-028457 Size: 221 KB Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 9.01: Financial Statements and Exhibits
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
GT Biopharma (NASDAQ:GTBP) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.08) by 50 percent. This is a 78.18 percent increase over losses of $(0.55) per share from the
Read original at benzingaGT Biopharma announced its third cancer drug, GTB-5550, entered Phase 1 clinical trials on May 14, 2026, marking the company's first expansion into solid tumors. Despite having three drugs in human trials—unusual for a micro-cap—the company trades at a significant valuation discount compared to peers, with only ~$9 million in cash and a runway into late 2026. The gap between its scientific promise and market valuation presents both opportunity and substantial risk, with near-term catalysts including clinical data updates and financing announcements expected in H2 2026.
Read original at benzinga